Dexcom (DXCM) Common Equity (2010 - 2026)

Dexcom (DXCM) has reported Common Equity for 17 consecutive years, with $2.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 1.88% year-over-year to $2.6 billion in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 1.88% increase from a year earlier, with the FY2025 full-year figure at $2.7 billion, up 30.6% from the prior year.
• Common Equity was $2.6 billion for Q2 2026 at Dexcom, down from $3.0 billion in the prior quarter.
• Over five years, Common Equity peaked at $3.0 billion in Q1 2026 and troughed at $1.8 billion in Q3 2022.
• A 5-year average of $2.3 billion and a median of $2.3 billion in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity fell 12.74% in 2024 and soared 37.75% in 2025, its largest moves.
• Over 5 years, Common Equity stood at $2.1 billion in 2022, then declined by 2.96% to $2.1 billion in 2023, then rose by 1.64% to $2.1 billion in 2024, then jumped by 30.6% to $2.7 billion in 2025, then retreated by 4.54% to $2.6 billion in 2026.
• The last three Common Equity figures came in at $2.6 billion (Q2 2026), $3.0 billion (Q1 2026), and $2.7 billion (Q4 2025), per Business Quant data.